摘要
目的 探讨FKBP脯氨酰异构酶10(FKBP10)、Ⅰ型胶原蛋白α1链(COL1A1)在肾癌组织中的表达及预后影响因素。方法 选取65例肾癌患者,采用定量聚合酶链反应(qPCR)法检测肾癌组织中FKBP10、COL1A1 mRNA表达水平,根据随访结果分为预后良好组和预后不良组,比较两组患者的FKBP10、COL1A1 mRNA表达水平;肾癌患者预后不良的影响因素采用Cox回归模型分析。结果 随访1年,65例肾癌患者中,预后不良20例,预后良好45例。预后不良组肾癌患者肾癌组织中FKBP10、COL1A1 mRNA表达水平均明显高于预后良好组,差异均有统计学意义(P﹤0.01)。单因素分析结果显示,肿瘤大小、TNM分期、病理类型、FKBP10表达情况、COL1A1表达情况均可能是肾癌患者预后不良的影响因素(P﹤0.05);多因素分析结果显示,FKBP10、COL1A1高表达均是肾癌患者预后不良的独立危险因素(P﹤0.05)。结论 FKBP10、COL1A1高表达与肾癌患者的预后不良有关,且均是肾癌患者预后不良的独立危险因素。
Objective To investigate the expression of FKBP prolyl isomerase 10(FKBP10)and type Ⅰ collagen alpha 1 chain(COL1A1)in renal carcinoma tissue and the prognostic factors.Method A total of 65 patients with renal carcinoma were selected,and the expression levels of FKBP10,COL1A1 mRNA in renal carcinoma tissues were detected by quantitative polymerase chain reaction(qPCR).According to the follow-up results,they were divided into good prognosis group and poor prognosis group,the expression levels of FKBP10,COL1A1 mRNA in two groups were compared.The influencing factors of poor prognosis in renal carcinoma patients were analyzed using Cox regression model.Result During 1-year follow-up,among 65 patients with renal carcinoma,20 cases had poor prognosis and 45 cases had good prognosis.The expression levels of FKBP10,COL1A1 mRNA in poor prognosis group were significantly higher than those in good prognosis group,and the differences were statistically significant(P<0.01).Univariate analysis results showed that tumor size,TNM stage,pathological type,FKBP10 expression,and COL1A1 expression may be influencing factors of poor prognosis in renal carcinoma patients(P<0.05).Multivariate analysis results showed that high expression of FK-BP10 and COL1A1 were independent risk factors for poor prognosis in renal carcinoma patients(P<0.05).Conclusion The high expression of FKBP10 and COL1A1 are closely related to poor prognosis of patients with renal carcinoma,and both are independent risk factors for poor prognosis.
作者
葛玉坤
胡容珲
杨红艳
韩露露
王磊
GE Yukun;HU Ronghui;YANG Hongyan;HAN Lulu;WANG Lei(Department of Urology,Xinxiang Central Hospital,Xinxiang 453000,He'nan,China;Key Laboratory of Clinical Medicine and Pharmacological Research of Urologic Nephropathy,Xinxiang Central Hospital,Xinxiang 453000,He'nan,China;The Fourth Clinical College of Xinxiang Medical University,Xinxiang 453000,He'nan,China)
出处
《癌症进展》
2024年第21期2380-2383,共4页
Oncology Progress
基金
河南省医学科技攻关计划联合共建项目(LHGJ20200958)。
